SeQure Dx, a leading genomics intelligence company, is presenting abstract 999, "Variant-aware off-target analysis of therapeutic CRISPR gene editing targets" at the 2023 American Society of Gene and Cell Therapy Annual Meeting Thursday poster session from 12pm to 2pm. SeQure Dx is dedicated to the advancement of on-target gene editing and cell therapies from discovery... Learn More

SeQure Dx, a leading genomics intelligence company, is presenting at the 2023 American Society of Gene and Cell Therapy Annual Meeting Startup Spotlight at 12:50PM, today May 17th. SeQure Dx is dedicated to the advancement of on-target gene editing and cell therapies from discovery to patient.  SeQure’s preclinical platforms for the biopharma industry, NoteSeQ and ScopeSeQ, comprise... Learn More

Read the press release... Learn More

Read the press release... Learn More

Nanopore sequencing offers a transformational new approach for robust and accurate genetic characterisation of biological materials, enabling the release of novel therapeutics with more certainty and safety assurance than ever before. OXFORD, England – March 21, 2023 – Oxford Nanopore Technologies plc (Oxford Nanopore) and PathoQuest... Learn More

Agathos Biologics launches analytical services Initial offerings focus on high-content imaging and digital PCR April 12, 2023 FARGO, N.D. - Agathos Biologics, a leading biotechnology company, is proud to... Learn More

Freudenberg, a global manufacturer of medical and pharmaceutical tubing, components, and devices, has introduced HelixFlex™, a high-purity thermoplastic elastomer TPE tubing designed for use in biopharmaceutical fluid transfer applications. This is an expanded offering from Freudenberg, adding to its existing pharma product portfolio of silicone tubing and components for bioprocessing, drug... Learn More

Financing will accelerate commercial roll-out of the company's cloud-based platform that provides a unified workspace for data-intensive biomedical research accessible by both biologists and bioinformaticians March 30, 2023 08:00 AM Eastern Daylight Time ... Learn More

TEMCELL Technologies Inc. and PBS Biotech Inc. have announced their supply partnership to make the PBS-MINI Bioreactor available through STEMCELL Technologies for researchers looking to scale up their human pluripotent stem cell (hPSC) cultures. By enabling the reliable and scalable suspension culture of hPSCs, this partnership will help scientists obtain... Learn More

CAMARILLO, Calif., Jan. 9, 2023 /PRNewswire/ -- PBS Biotech ("PBS"), an innovative, single-use bioreactor manufacturer and process development services provider, has completed a $22 million financing led by Avego Management, LLC ("Avego") with additional investment from existing investor BroadOak Capital Partners ("BroadOak"). This financing will be used to improve the company's products portfolio, expand... Learn More

Recently, researchers announced that they have found a new target for inhibiting vascular endothelial growth factor (VEGF), which can improve the symptoms of ophthalmic diseases. This is achieved by affecting the release of VEGF and choroidal neovascularization through fat mass and obesity-associated protein (FTO) inhibition. These findings provide a new... Learn More

Have you ever wondered what the future of science education looks like? Many envision a future of readily accessible science knowledge and facts presented by intelligent, interactive teachers. Given the limited time and resources available from top teaching talent, there is an increasing demand for engaging scientific learning that could... Learn More

Original Article   Cyagen today announced a strategic collaboration with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders. Under the terms of the agreement, Cyagen will apply its proprietary artificial intelligence (AI)-powered... Learn More

Recently, Cyagen and Guangdong Landau Biotechnology Co., Ltd. (hereinafter referred to as "Landau Biotech") strengthened their strategic partnership on the basis of the original strategic cooperation. A new consensus will be reached on the joint focus for the development of AAV gene therapy vectors, and will fully utilize the collective resources, technologies, and brand advantages... Learn More

Our comprehensive services cover the entire process of model generation: from transgenic/gene targeting strategy design, through model development, breeding, cryopreservation, and phenotype analysis. Our CRO service platforms provide everything required for drug discovery and preclinical research, including specialty cell and gene therapy (CGT) therapeutic areas, such... Learn More

Leiden, The Netherlands, June 28, 2022 – Today, Batavia Biosciences  announces that it will extend its CDMO services portfolio (R&D and clinical manufacturing) to include commercial manufacturing services. The company has finalized the design plans of its new 12.000 square meter building to be realized at the Bioscience Park in Leiden, The... Learn More

Announced October 10, 2022 With original operations based in The Woodlands, TX, industry-recognized plasmid DNA contract manufacturer VGXI, Inc. celebrated the official Grand Opening of its new headquarters and expanded manufacturing facility in Conroe, TX. ... Learn More

Milpitas, California, August 29, 2022 -- Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today... Learn More